Synthetic control arms are no longer a research curiosity. The major regulators now accept them in defined contexts, and that acceptance is changing how trials are designed.
What the regulator now accepts
Specific indications, well-characterised populations, and rigorous prospective registries — the synthetic arm has to earn its place by being honest about its assumptions.
What changes for sponsors
Trial cost, time, and ethics calculus all shift. The platform that supports synthetic design will be a competitive asset — and the data partnerships that feed it will be the new strategic relationships.